Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women

Fertility and Sterility

Volumn 88, Issue 4, 2007, Pages 866-878

  Archer, David F ^a   Hendrix, Susan ^b   Ferenczy, Alex ^c   Felix, Juan ^d   Gallagher, J Chris ^e   Rymer, Janice ^f   Skouby, Sven O ^g   den Hollander, Wil ^h   Stathopoulos, Victoria ⁱ   Helmond, Frans A ⁱ  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g FREDERIKSBERG HOSPITAL   (Denmark)

^h NV ORGANON   (Netherlands)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

breast tenderness; endometrial cancer; endometrial histology; endometrial hyperplasia; endometrial safety; estrogen; hormone therapy; progestin; Tibolone; vaginal bleeding

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST; CELL PROLIFERATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MENSTRUATION; MULTICENTER STUDY; PARALLEL DESIGN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCREENING; SECRETION; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING; VAGINAL DRYNESS; WEIGHT CHANGE;

AGED; BREAST; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; PAIN; POSTMENOPAUSE; VACUUM CURETTAGE;

EID: 34848917549     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.12.052     Document Type: Article

References (48)

1. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (1995) 304-313
2. Lethaby A., Suckling J., Barlow D., Farquhar C.M., Jepson R.G., and Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 3 (2004) CD000402
3. Gambacciani M., Monteleone P., Sacco A., and Genazzani A.R. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 17 (2003) 139-147
4. Van Gorp T., and Neven P. Endometrial safety of hormone replacement therapy: review of literature. Maturitas 42 (2002) 93-104
5. Pickar J.H., Thorneycroft I., and Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 178 (1998) 1087-1099
6. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
7. Panay N., and Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 3 (1997) 159-171
8. Genazzani A.R., Monteleone P., and Gambacciani M. Hormonal influence on the central nervous system. Maturitas 43 Suppl. 1 (2002) S11-S17
9. Zweifel J.E., and O'Brien W.H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 22 (1997) 189-212
10. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
11. Magnusson C., Baron J.A., Correia N., Bergstrom R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 (1999) 339-344
12. Ross R.K., Paganini-Hill A., Wan P.C., and Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92 (2000) 328-332
13. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
14. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
15. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25 (2004) 45-71
16. Markiewicz L., and Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 35 (1990) 535-541
17. Tang B., Markiewicz L., Kloosterboer H.J., and Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 45 (1993) 345-351
18. de Gooyer M.E., Deckers G.H., Schoonen W.G., Verheul H.A., and Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68 (2003) 21-30
19. de Gooyer M.E., Kleyn G.T., Smits K.C., Ederveen A.G., Verheul H.A., and Kloosterboer H.J. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 183 (2001) 55-62
20. Cline J.M., Register T.C., and Clarkson T.B. Comparative effects of tibolone and conjugated equine estrogens with and without medroxyprogesterone acetate on the reproductive tract of female cynomolgus monkeys. Menopause 9 (2002) 242-252
21. Genazzani A.R., Benedek-Jaszmann L.J., Hart D.M., Andolsek L., Kicovic P.M., and Tax L. Org OD 14 and the endometrium. Maturitas 13 (1991) 243-251
22. Volker W., Coelingh Bennink H.J., and Helmond F.A. Effects of tibolone on the endometrium. Climacteric 4 (2001) 203-208
23. Wender M.C., Edelweiss M.I., Campos L.S., de Castro J.A., and Spritzer P.M. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 11 (2004) 423-429
24. Bruce D., Robinson J., and Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 7 (2004) 261-266
25. Hanggi W., Bersinger N., Altermatt H.J., and Birkhauser M.H. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas 27 (1997) 133-143
26. Doren M., Rubig A., Coelingh Bennink H.J., and Holzgreve W. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 6 (1999) 299-306
27. de Vries C.S., Bromley S.E., Thomas H., and Farmer R.D. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Saf 28 (2005) 241-249
28. Beral V., Bull D., and Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
29. Wierik E.J., Hendricks P.T., and Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. Climacteric 7 (2004) 197-209
30. Landgren M.B., Bennink H.J., Helmond F.A., and Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 109 (2002) 1109-1114
31. Gallagher J.C., Baylink D.J., Freeman R., and McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86 (2001) 4717-4726
32. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
33. Pickar J.H., Yeh I., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76 (2001) 25-31
34. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275 (1996) 370-375
35. Pickar J.H., Yeh I.T., Wheeler J.E., Cunnane M.F., and Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 80 (2003) 1234-1240
36. US Food and Drug Administration. Guidance for clinical evaluation of combination estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women. Research, FCfDEa, Editor. 1995.
37. Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. CPMP/EWP/021/97. London, 1997.
38. Sherman M., Mazur M., and Kurman R. Benign diseases of the endometrium. In: Kurman R. (Ed). Blaustein's pathology of the female genital tract (2002), Springer, New York 421-466
39. Ronett B., and Kurman R. Precursor lesions of endometrial carcinoma. In: Kurman R. (Ed). Blaustein's pathology of the female genital tract (2002), Springer, New York 467-500
40. American College of Radiology. Illustrated Breast Imaging Reporting and Datasystems (BI-RADS). 3rd ed. (1998), American College of Radiology, Reston, VA
41. Byng J.W., Yaffe M.J., Jong R.A., Shumak R.S., Lockwood G.A., Tritchler D.L., et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 18 (1998) 1587-1598
42. Wiklund I., Karlberg J., and Mattsson L.A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 168 (1993) 824-830
43. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 7 (1992) 45-54
44. McCoy N.L., and Davidson J.M. A longitudinal study of the effects of menopause on sexuality. Maturitas 7 (1985) 203-210
45. McCoy N.L. Methodological problems in the study of sexuality and the menopause. Maturitas 29 (1998) 51-60
46. Legault C., Espeland M.A., Wasilauskas C.H., Bush T.L., Trabal J., Judd H.L., et al. Agreement in assessing endometrial pathology: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health 7 (1998) 435-442
47. Archer D.F., McIntyre-Seltman K., Wilborn Jr. W.W., Dowling E.A., Cone F., Creasy G.W., et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 165 (1991) 317-320
48. Korhonen M.O., Symons J.P., Hyde B.M., Rowan J.P., and Wilborn W.H. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 176 (1997) 377-380